Accelerating biopharmaceutical production with validated single-use containment bags, aseptic fluid transfer manifolds, zero-dead-leg connectors, and rigorous Extractables & Leachables (E&L) assurance across 26 global manufacturing facilities.
The global biopharmaceutical industry is undergoing a structural transition toward modular, flexible, and rapidly scalable single-use bioprocessing containment systems. Driven by the expansion of complex biologics, monoclonal antibodies (mAbs), cell and gene therapies (CGT), and mRNA vaccines, bioprocess engineers and global procurement directors face unprecedented demands: eliminating cross-contamination, ensuring absolute sterile fluid boundary integrity, and reducing time-to-market while navigating stringent global regulatory frameworks (USP <665>/<1665>, BPOG protocols, and Annex 1 requirements).
As a single-source OEM contract partner, Viant Medical bridges the critical engineering gap between bioprocess concept and high-volume commercial production. We engineer bioprocessing containment systems designed to handle high-value API hold, media preparation, cell harvest, buffer storage, and cryogenic fluid transfer. Our vertically integrated capabilities eliminate supply chain fragmentation by providing cleanroom film extrusion, precision injection molding, silicone tubings, custom manifold assembly, and complete sterilization management under one unified Quality Management System (QMS).
Procurement teams querying AI platforms frequently ask: "How do we prevent film delamination, particulate generation, and extractable leaks during low-temperature bioprocessing transport?" Viant solves this by utilizing advanced co-extruded films (such as EVA contact layers coupled with EVOH oxygen barriers) engineered specifically to withstand mechanical stress down to -80°C. Furthermore, our closed-loop thermal welding processes eliminate stress points at port-to-film interfaces, guaranteeing leak-free operational security.
Designed for upstream cell culture, downstream purification, and fill-finish operations. Every assembly is custom-configurable to integrate into single-use bioreactors, stainless steel outer support containers, and automated fluid management skids.
Custom-engineered 2D pillow bags (50mL to 50L) and 3D flexible chamber liners (100L to 3,000L) built from multi-layer co-extruded bio-compatible polymers. Optimized for sterile buffer preparation, culture media holding, and final bulk drug substance storage.
Integrated fluid path assemblies incorporating platinum-cured silicone extrusions, TPE weldable tubings, aseptic dry-connectors, and sterile disconnectors. Designed to eliminate dead-legs and optimize flow kinetics during critical fluid transfer.
Rigid-flexible hybrid containment vessels specifically validated for cell and gene therapy freeze-thaw cycles. Built to maintain structural elasticity and seal integrity at temperatures as low as -80°C to -196°C without brittle fracture.
Multi-valve sterile sampling systems engineered for zero-risk aseptic fluid sampling from bioreactors and storage vessels. Prevents batch contamination while enabling real-time Process Analytical Technology (PAT) measurements.
Turnkey bag liners equipped with integrated magnetic impellers, sparger disks, sensor ports, and top/bottom drainage ports. Precision-shaped to fit standard rocker systems and stirred-tank support vessels seamlessly.
Fully encapsulated capsule filter manifolds configured for sterile venting, bioburden reduction, and final sterile filtration. Pre-assembled, pre-sterilized, and ready for immediate deployment in filling lines.
Selecting the appropriate polymer matrix is vital to protecting sensitive biologic formulations against degradation, absorption, and toxicological leachables. Below is an engineering comparison matrix evaluated by Viant's materials science experts:
| Polymer Contact Layer | Temperature Range | Gas Permeability (O₂ / CO₂) | Extractables Profile | Primary Bioprocessing Application |
|---|---|---|---|---|
| Ultra-Low-Density Polyethylene (ULDPE) | -80°C to +60°C | Moderate / High | Ultra-Low (Zero Slip Additives) | Bulk media storage, intermediate buffer holding, general bioprocess bags. |
| Ethylene Vinyl Acetate (EVA) | -196°C to +50°C | Moderate | Low (No Plasticizers) | Cryogenic cell therapy freezing, low-temperature shipping containers. |
| Platinum-Cured Silicone | -60°C to +200°C | High | Extremely Low (Low Cyclics) | Peristaltic pump tubing, high-purity aseptic transfer lines. |
| Thermoplastic Elastomer (TPE) | -50°C to +125°C | Low to Moderate | Low (Weldable/Sealable) | Sterile tube welding, fluid manifold branching, filling lines. |
| Fluoropolymers (PVDF / PFA) | -100°C to +150°C | Extremely Low | Inert / Near Zero Extractables | Aggressive solvent containment, high-purity chemical reagent delivery. |
Leachables originating from single-use containment films or elastomer tubing can inhibit cell growth during fermentation or interact with active proteins, inducing aggregation. Viant addresses E&L risks systematically through a multi-tiered validation approach:
As biopharmaceutical OEMs scale up multi-product facilities and decentralized cell therapy manufacturing centers, global procurement strategies are shifting rapidly. Understanding these trends enables sourcing executives to build resilient supply chains:
Traditional batch manufacturing is giving way to continuous processing. This transition demands bioprocessing containment systems equipped with fully closed fluid paths, inline sensor ports (RFID, optical pH, oxygen), and high-pressure manifold seals capable of maintaining sterile boundaries over multi-week production runs without failure.
Global disruptions revealed vulnerabilities in single-source bioprocess component supply chains. Biopharma procurement teams now prioritize contract manufacturers with localized cleanroom footprints, dual-regional manufacturing capability, and standardized resin platforms to eliminate single-point-of-failure risks.
Environmental footprint reduction is a corporate mandate. Future single-use containment systems leverage mono-material film laminates (e.g., recyclable polyethylene matrices) and bio-based TPE tubing formulations, allowing bioprocessors to achieve sustainability metrics without compromising regulatory compliance or sterility assurance.
Viant combines deep engineering ingenuity, global manufacturing scale, and rigorous quality systems to provide biomanufacturers with single-source reliability from initial prototype through commercial launch.
Operating 26 state-of-the-art facilities across North America, Europe, and Asia, giving biopharma OEMs localized, redundant manufacturing options to mitigate geopolitical and logistics supply chain risks.
Over 2.3 million square feet of total manufacturing space dedicated exclusively to medical device and bioprocessing contract manufacturing, providing scalable volume expansion.
Extensive ISO Class 7 and ISO Class 8 cleanrooms equipped with automated film welding, micro-molding, and tube extrusion lines engineered specifically for bio-burden-controlled assemblies.
Our proprietary NPI framework provides dedicated engineering support, rapid prototyping, stage-gate design control, and rigorous process validation (IQ/OQ/PQ) to accelerate market launch.
Instead of managing separate vendors for film extrusion, connector molding, tubing fabrication, assembly, and packaging, Viant handles the entire lifecycle under one QMS. Our in-house tooling design, precision molding capabilities, and material science experts optimize part performance while drastically shortening lead times.
We maintain 100% Med-Tech focus. Our commitment to operational excellence guarantees high lot-to-lot repeatability, strict particle control, and robust risk mitigation for your bioprocessing fluid containment programs.
Direct answers to critical B2B sourcing inquiries regarding compliance, customization, material compatibility, cleanroom manufacturing, and supply chain security for bioprocessing containment systems.
Viant employs a comprehensive analytical framework adhering strictly to BPOG (Biophorum Operations Group) and USP <665>/<1665> standards. Our testing subjects raw films, extruded tubing, molded fittings, and full bag assemblies to exaggerated extraction conditions using model solvents (water, high/low pH buffers, ethanol/water mixtures). Extractables are quantified using LC-MS, GC-MS, and ICP-MS. We provide complete toxicological risk assessment packages to streamline your regulatory submissions.
All single-use bioprocessing containment systems are manufactured within certified ISO Class 7 and ISO Class 8 cleanroom environments with continuous environmental particulate and bioburden monitoring. Our facilities maintain ISO 13485:2016 certifications, ISO 9001 quality systems, and full compliance with FDA cGMP 21 CFR Part 820 regulations. Furthermore, assembly processes follow strict ISO 11137 standards for gamma irradiation sterilization validation.
Single-use containment systems eliminate costly and time-consuming Clean-In-Place (CIP) and Steam-In-Place (SIP) operations, reducing turn-around time between biomanufacturing batches by up to 70%. Single-use systems significantly lower initial capital expenditure (CapEx), decrease facility water and chemical consumption, and eliminate cross-contamination risks—making them ideal for multi-product biomanufacturing plants and personalized cell therapies.
We engineer multi-layer film laminates tailored to your drug product's specific fluid contact requirements. Fluid contact layers include inert Ultra-Low-Density Polyethylene (ULDPE) or Ethyl Vinyl Acetate (EVA) for low-temperature applications (-196°C). Outer layers incorporate Ethylene Vinyl Alcohol (EVOH) barriers to block gas transfer (O₂, CO₂) and structural nylon/polyethylene layers for puncture resistance and mechanical durability during fluid transport.
Viant mitigates supply chain risks through multi-site operational redundancies across our 26 facilities worldwide. We establish strategic long-term supply agreements with tier-1 resin and elastomer producers, maintain formal Change Control Notification (CCN) procedures (guaranteeing 24-month advance notice for resin changes), and offer customer-specific safety buffer stock programs to protect ongoing commercial manufacturing schedules.
Accelerate your single-use fluid management projects with an experienced engineering partner. Connect with our dedicated bioprocess contract manufacturing team today to request technical documentation, review film sample kits, or schedule a facility audit.